Published in Cancer Weekly, May 1st, 2006
"Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases. Twenty-three patients with advanced inoperable melanoma were hospitalized for 5-6 days for the following treatment: cisplatin 20 mg/m2 daily for 4 days, vinblastine 1.6 mg/m2 daily for 4 days and oral temozolomide 250 mg/m2 daily for 5 days, with 18 x 106 IU/m2 intravenous interleukin-2 by continuous infusion for 4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.